

2 February 2024
RNS Reach

Physiomics plc
("Physiomics" or "the Company")

IMC Presentation on Company Website

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update on the Board changes via *Investor Meet Company* and has updated its website with the presentation.

The presentation and Q&A from the meeting are now available at the Company's website:
www.physiomics.co.uk/portfolio-item/investor-presentation-board-changes

Enquiries:

Physiomics plc

Dr Jim Millen, Non-Executive Chairman, +44 (0)1235 841575

Dr Peter Sargent, Chief Executive Officer, +44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEAXAFEDXLEFA